Intravitreal Adalimumab for Refractory Uveitis-Related Macular Edema

Objective To evaluate the safety and efficacy of intravitreal adalimumab injections on refractory cystoid macular edema (CME) secondary to noninfectious uveitis. Design Prospective, noncomparative, interventional case series. Participants Eight consecutive patients with controlled uveitis and chronic, refractory CME who had failed steroid treatment. Intervention Intravitreal adalimumab injections were given monthly for 3 months. Main Outcome Measures Mean change in central retinal thickness (CRT) on optical coherence tomography (OCT); secondary objective was the mean change in best-corrected visual acuity (BCVA). Results Five of the eight patients completed the 6-month follow-up. For all 5 patients, the changes in BCVA from baseline to 3 months were not statistically significant ( P= 0.070). Similarly, the change in BCVA from baseline to 6 months was not statistically significant ( P= 1.0). The mean CRT at baseline was 692 μm. The changes from baseline to 3 months were not statistically significant ( P= 0.466); the changes from baseline to 6 months were also not statistically significant ( P= 0.808). We did not observe any ocular or systemic adverse effects. Conclusions Intravitreal adalimumab showed no efficacy in improving BCVA or reducing CRT in patients with chronic uveitic macular edema. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article.